L858R point mutation

Pulmonary pleomorphic carcinoma is a very rare histological type of primary lung cancer, and usually provides aggressive clinical courses. A 65-year-old Japanese woman was diagnosed by transbronchial biopsy of the primary tumor as c-stage IV (cT4N3M1b) of adenocarcinoma harboring L858R point mutation in the exon 21 of epidermal growth factor receptor (EGFR).

5p viintuit 26-09-2023 3 0   Download

Non-small cell lung cancer (NSCLC) with activating EGFR mutations, especially exon 19 deletions and the L858R point mutation, is particularly responsive to gefitinib and erlotinib. However, the sensitivity varies for less common and rare EGFR mutations.

13p viconnecticut2711 28-10-2020 19 1   Download

LUX-Lung 3 showed afatinib improved progression-free survival (PFS) compared with cisplatin plus pemetrexed in patients with epidermal growth factor receptor (EGFR) mutations.

8p vibaku2711 22-07-2020 9 2   Download

Non - small cell lung cancer (NSCLC) is the largest subgroup of lung cancers, responsible for about 80% of all lung cancers. Targeted cancer therapy has opened a new window into treatment of non - small cell lung cancer. This therapy is very effective for patients who have EGFR (Epidermal growth factor receptor) activating mutations, primarily located in the tyrosine kinase domain in the form of a base - pair deletion at exon 19 (LREA deletions, accounting for about 54%) or a point mutation at exon 21 (L858R, accounting for about 43%).

9p quenchua1 04-11-2019 11 0   Download